Clinical study of CAR-T Therapy in Relapsed or Refractory Haematopoietic and Lymphoid Malignancies

Entering the 21st century ,several tumor immunotherapy success in clinical trial make the immunotherapy very hot in research field. Especially after 2010, CAR-T cell immunotherapy have an amazing effect on B cell Malignant Tumors.

What is CAR-T cell immunotherapy? T cells are collected from a patient,they are genetically engineered to produce chimeric antigen receptors (CARs) on their surface.After this reengineering, the T cells are known as “chimeric antigen receptor (CAR) T cells.” CARs are proteins that allow the T cells to recognize an antigen on targeted tumor cells.The CAR T cells are then infused into the patient and they are the “attacker” cells that will recognize, and kill, cancerous cells that have the targeted antigen on their surface.

Hebei Senlang Biotechnology Co., Ltd together Second Hospital of Hebei Medical University develop the CAR-T cell immunotherapy clinical study ,use the CD19 as target for CD19+ Patients With Relapsed or Refractory Blood Malignant Tumors ( main including ALL and B-cell Lymphoma)